Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
September 19, 2024 07:00 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the...
Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring
September 18, 2024 07:00 ET
|
Vivos Therapeutics, Inc
Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing and distribution model Vivos’ DNA appliance now...
Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
August 14, 2024 16:05 ET
|
Vivos Therapeutics, Inc
Revenue Increased 19% both Sequentially and Year over Year Operating Expenses Decreased 31%, Marking Eight Consecutive Quarters of Year Over Year Improvement Due to Successful Cost Cutting...
Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call
August 14, 2024 07:30 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the...
Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model
June 27, 2024 07:30 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., June 27, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company” (NASDAQ:VVOS), a leading medical device and technology company specializing in the development...
Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance
June 12, 2024 07:30 ET
|
Vivos Therapeutics, Inc
Alliance with Sleep Treatment Provider in Colorado Marks Critical Pivot in Vivos’ Marketing and Distribution Model Aimed at Enhancing Revenue Streams and Potential Profit Private Placement Investment...
Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update
May 14, 2024 16:05 ET
|
Vivos Therapeutics, Inc
Vivos Expanding its Revenue Generating InitiativesAs Operating Expenses Decrease 22%, Representing Seven Consecutive Quarters ofYear Over Year Improvement Due to Successful Cost Cutting Initiatives ...
Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call
May 14, 2024 07:30 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., May 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development...
Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement
April 09, 2024 07:30 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the...
Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update
March 28, 2024 16:05 ET
|
Vivos Therapeutics, Inc
Positive Business Momentum and Sales Pipeline Growth Following FDA 510(k) Clearance of Vivos’ Proprietary Oral Medical Devices to Treat Severe Obstructive Sleep Apnea Annual Operating Expenses...